TME Pharma announces oral presentation at ESMO 2024 with updated results from NOX-A12 GLORIA Phase 1/2 study in glioblastoma Page 1

Regulatory news:

TME Pharma NV (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor microenvironment (TME), announced an oral presentation by Frank A. Giordano, M.D., principal investigator of the Phase 1/2 NOX-A12 GLORIA trial in first-line brain cancer (glioblastoma), to be held on Sunday, September 15, 2024, at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. The presentation presented updated results and key conclusions from combination therapy with NOX-A12 and bevacizumab in newly diagnosed glioblastoma patients who were resistant to standard chemotherapy (MGMT unmethylated) and had residual tumor after surgery.

In his presentation, Dr. Giordano highlighted that inhibiting two pathways of brain tumor revascularization after radiation – vasculogenesis with NOX-A12 and angiogenesis with bevacizumab – resulted in deeper clinical responses, i.e., greater shrinkage of tumor size, compared to NOX-A12 therapy alone. The research showed a significant decrease in tumor blood flow, supporting the proposed mode of action of the combination therapy. The presentation also shows that the deeper responses to combination therapy with NOX-A12 and bevacizumab lead to significantly longer median progression-free survival (mPFS: 9.1 months, p=0.003) and median overall survival (mOS: 19.9 months, p=0.005) compared to a matched SOC reference cohort (mPFS: 4.0 months; mOS: 9.5 months) or to NOX-A12 alone (mPFS: 5.7 months; mOS: 12.7 months). Two of the six glioblastoma patients in the NOX-A12 + bevacizumab arm of the GLORIA study survived more than 26 months since the start of therapy.

“The median overall survival of 19.9 months achieved in patients who received combination therapy in the GLORIA trial is particularly exciting when one considers the prognosis that this chemotherapy-refractory patient group with detectable residual tumor after surgery would otherwise have with current standard treatment, particularly a survival time of approximately 10 months,” said Aram Mangasarian, CEO of TME Pharma. “Further strengthening our confidence in our dual inhibition approach is tumor tissue analysis showing spatially distinct expression patterns of NOX-A12's target molecule CXCL12 and VEGF. This suggests that the two different pathways of blood vessel growth occur in different tumor structures: vasculogenesis is controlled by the NOX-A12 target molecule, and angiogenesis is controlled by the bevacizumab target molecule. This helps explain why combined inhibition of both pathways is required to effectively prevent tumor vascular recovery after radiotherapy.”